• <center id="my6c6"></center>
    <rt id="my6c6"><acronym id="my6c6"></acronym></rt>
  • <abbr id="my6c6"></abbr>
  •  

    上海強世信息科技有限公司

    Exposure–safety relationship of trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer (MBC).
    作者: | 發布:Chunze Li, Bei Wang, Dan Lu, Jin Y Jin, Yuying Gao, Kiyoshi Matsunaga, Yuriko Igawa and Sandhya Girish. | 發布時間: 2013-03-20 | 301 次瀏覽 | 分享到:
    Abstract
    Background: Trastuzumab emtansine (T-DM1) is an antibody–drug conjugate composed of trastuzumab, the cytotoxic agent DM1, and a stable thioether linker. The effects of T-DM1 exposure on safety in patients with HER2-positive locally advanced or MBC are reported. Methods: The exposure–safety analysis included 618 patients with pharmacokinetic (PK) data who received single-agent T-DM1 3.6 mg/kg q3w from five phase 2 or 3 studies: TDM4258g, TDM4374g, TDM4450g/BO21976, TDM4688g, and EMILIA. Exposure parameters observed in cycle 1 were T-DM1 conjugate AUC, T-DM1 conjugate Cmax, and DM1 Cmax, (no PK accumulation). Safety endpoints were worst grade of thrombocytopenia (TCP) or hepatotoxicity (HPT) by protocol definitions. A multivariate logistic regression analysis was conducted to evaluate the association of exposure and clinically relevant covariates with the probability of experiencing TCP or HPT. Platelet counts (PLT), alanine transaminase (ALT), aspartate transaminase (AST), and total bilirubin (TBL) versus time profiles were also evaluated by exposure quartiles to further test exposure effect on lab values. A secondary analysis for patients in the EMILIA study alone (n=307) was also conducted. Results: Grade ≥3 TCP and grade≥ 3 HPT were observed in 72 patients and 45 patients in the exposure–safety data set, respectively. Data from the pooled studies showed no statistically significant association between exposure and the incidence of grade ≥3 TCP (T-DM1 AUC P=0.99, T-DM1 Cmax P=0.97, DM1 Cmax P=0.72), or grade ≥3 HPT (T-DM1 AUC P=0.25, T-DM1 Cmax P=0.93, DM1 Cmax P=0.95). Additionally, no obvious difference was observed for longitudinal PLT, ALT, AST, or TBL profiles across exposure quartiles, with no exposure–safety relationship for the probability that PLT, ALT, AST, or TBL exceeded grade 3 thresholds. Similar results were observed for the EMILIA analysis. Conclusions: For patients with HER2-positive locally advanced or MBC treated with T-DM1 3.6 mg/kg q3w, no exposure–safety relationship was observed for TCP, HPT, PLT, or liver function based on T-DM1 or DM1 exposure.

    Journal of Clinical Oncology 2013 31:15_suppl, 646-646

    https://ascopubs.org/doi/abs/10.1200/jco.2013.31.15_suppl.646


    久久99精品久久久久子伦| 中文精品久久久久国产网址| 久久精品国产99国产精品澳门| 99久久国产精品免费一区二区| 久久国产成人精品| 久久www免费人成看片| 很黄很污的网站久久mimi色| 中文字幕乱码久久午夜| 国产精品久久久久三级| 伊人久久精品无码二区麻豆| 91精品国产91久久久久久| 久久精品国产99久久| 午夜精品久久久久久久99蜜桃| 久久久久人妻精品一区三寸蜜桃| 久久久久国产免费| 国产午夜精品久久久久九九| 91精品国产综合久久久久| 久久天天躁夜夜躁狠狠躁2015| 波多野结衣中文字幕久久| 国产高潮国产高潮久久久91| 色天天综合久久久久综合片| 久久国产精品自由自在| 伊人久久综合无码成人网| 精品人妻伦九区久久AAA片69 | 久久亚洲精精品中文字幕| 一本大道久久香蕉成人网| 久久久久久亚洲av成人无码国产| 伊人久久波多野结衣中文字幕| 亚洲&#228;v永久无码精品天堂久久 | 国内精品久久久久久久久| 精品无码人妻久久久久久| 啊灬啊灬啊灬快灬深久久| 色综合久久天天综合绕观看| 精品久久久久久无码中文字幕一区| 久久久久久亚洲精品影院| 久久国产亚洲精品麻豆| 一本色道久久HEZYO无码| 久久综合视频网站| 99久久精品国内| 影音先锋女人AV鲁色资源网久久| 99久久综合狠狠综合久久止|